Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

Precision Antibody wins NCI contract to develop monoclonal antibody reagents
December 2009
SHARING OPTIONS:

COLUMBIA, Md.Precision Antibody has been selected as the antibody developer for a component of the National Cancer Institute (NCI)'sClinical Proteomic Technologies for Cancer (CPTC), a five-year, $104 million initiative focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research. The contract award is the result of a third solicitation for contract proposals from custom antibody suppliers as part of the Clinical Proteomic Reagents Resources component of the CPTC, whose mission is to develop high-quality, standardized, renewable reagents that are needed for effective proteomic analysis. Precision Antibody will apply its rapid antibody-generation technology to develop three monoclonal antibodies against each of 20 cancer-related target antigens produced by Argonne National Laboratory that have been identified to be of high interest to the cancer proteomics community. Other terms were not disclosed.

 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.